Drug Profile
Research programme: potassium channel activators - Knopp Biosciences
Alternative Names: KCNQ2 potassium channel activators - Knopp Biosciences; Kv7 channel activators; Kv7 modulator; Kv7.2/7.3 channel activatorsLatest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Knopp Biosciences
- Class Amides; Analgesics; Benzimidazoles; Small molecules
- Mechanism of Action KCNQ3 potassium channel stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Amyotrophic lateral sclerosis; Hearing disorders
- No development reported Neuropathic pain; Tinnitus
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (Topical)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Tinnitus in USA